Literature DB >> 23245837

Comparison of variables in men versus women undergoing transcatheter aortic valve implantation for severe aortic stenosis (from Italian Multicenter CoreValve registry).

Paolo Buja1, Massimo Napodano, Corrado Tamburino, Anna Sonia Petronio, Federica Ettori, Gennaro Santoro, Gian Paolo Ussia, Silvio Klugmann, Francesco Bedogni, Angelo Ramondo, Francesco Maisano, Antonio Marzocchi, Arnaldo Poli, Valeria Gasparetto, David Antoniucci, Antonio Colombo, Giuseppe Tarantini.   

Abstract

Although transcatheter aortic valve implantation (TAVI) for severe aortic stenosis is becoming an established technique, the effect of gender-related differences is poorly described. We performed a gender-based comparison of high-risk patients undergoing TAVI with the self-expandable CoreValve Revalving System for severe aortic stenosis to evaluate early and mid-term clinical outcomes. From the Italian prospective CoreValve registry, 659 consecutive patients (55.8% women) who underwent TAVI were included in the present study. We analyzed the gender-based differences in terms of clinical, angiographic, and procedural features and the differences in the rate of early and mid-term major adverse cardiac and cerebrovascular events. The men were younger, presented more often with severe left ventricular dysfunction, and had a greater rate of previous myocardial infarction, coronary revascularization, peripheral artery disease, renal failure, and heart conduction disorders than the women. The logistic European System for Cardiac Operative Risk Evaluation score did not differ between the 2 groups. The overall unadjusted and adjusted analyses failed to show significant differences between genders in terms of major adverse cardiac and cerebrovascular events at a median follow-up of 13 months (range 8 to 18). At late follow-up (landmark analysis >12 months), a survival benefit was observed in women (hazard ratio 0.27, 95% confidence interval 0.09 to 0.84, p = 0.02). In conclusion, in this multicenter registry, the gender-based comparison of TAVI patients showed that men, despite the younger age, had more extensive atherosclerotic burden compared to women. Overall, the early and mid-term outcomes were similar between genders, although women might have a survival benefit with longer follow-up.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23245837     DOI: 10.1016/j.amjcard.2012.08.051

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Another passenger for the TAVR speeding train.

Authors:  Chiara Fraccaro; Daisuke Ueshima; Giuseppe Tarantini
Journal:  Ann Transl Med       Date:  2017-08

Review 2.  Sex-Specific Considerations in Women with Aortic Stenosis and Outcomes After Transcatheter Aortic Valve Replacement.

Authors:  Christos G Mihos; Sheila L Klassen; Evin Yucel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-06-19

Review 3.  Transcatheter aortic valve replacement in women.

Authors:  Dipti Itchhaporia
Journal:  Clin Cardiol       Date:  2018-02-27       Impact factor: 2.882

Review 4.  European real world trans-catheter aortic valve implantation: systematic review and meta-analysis of European national registries.

Authors:  G Krasopoulos; F Falconieri; U Benedetto; J Newton; R Sayeed; R Kharbanda; A Banning
Journal:  J Cardiothorac Surg       Date:  2016-11-29       Impact factor: 1.637

5.  Female gender and the clinical and periprocedural profile and clinical outcomes of transcatheter aortic valve implantation: experiences of a tertiary Polish centre.

Authors:  Krzysztof Wilczek; Piotr Chodór; Maciej Dyrbuś; Michał Hawranek; Łukasz Włoch; Łukasz Pyka; Tomasz Hrapkowicz; Michał Zembala; Zbigniew Kalarus; Mariusz Gąsior
Journal:  Postepy Kardiol Interwencyjnej       Date:  2020-12-29       Impact factor: 1.426

Review 6.  Sex and Transcatheter Aortic Valve Implantation: Impact of Female Sex on Clinical Outcomes.

Authors:  Alessandra Laricchia; Barbara Bellini; Vittorio Romano; Saud Khawaja; Matteo Montorfano; Alaide Chieffo
Journal:  Interv Cardiol       Date:  2019-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.